Cornejo-Estrada Alejandra, Nieto-Rodríguez Carlos, León-Figueroa Darwin A, Moreno-Ramos Emilly, Cabanillas-Ramirez Cielo, Barboza Joshuan J
School of Medicine, Universidad Peruana de Ciencias Aplicadas, Lima 15067, Peru.
Facultad de Medicina Humana, Universidad de San Martín de Porres, Chiclayo 15011, Peru.
Children (Basel). 2023 Jan 25;10(2):208. doi: 10.3390/children10020208.
In the past few decades, childhood obesity has become a significant global health issue, impacting around 107.7 million children and adolescents globally. There is currently minimal usage of pharmacological therapies for childhood obesity in the pediatric population. This research assessed the efficacy of liraglutide in treating childhood and adolescent obesity. Until 20 October 2022, a systematic literature review was done utilizing PubMed, Scopus, Web of Science, and Embase databases. The search phrases "liraglutide", "pediatric obesity", "children", and "adolescents" were utilized. Using the search method, a total of 185 articles were found. Three studies demonstrating liraglutide's effectiveness in treating child and adolescent obesity were included. The selected research was done in the United States. As an intervention, liraglutide was administered to 296 participants at a maximal dosage of 3.0 mg. All examined trials were in phase 3. This comprehensive analysis revealed no clinically significant differences between liraglutide and body weight (kg; MD -2.62; 95%CI -6.35 to 1.12; = 0.17) and body mass index (kg/m; MD -0.80; 95%CI -2.33 to 0.73, = 0.31). There was no evidence that liraglutide increased hypoglycemia episodes (RR 1.08; 95%CI 0.37 to 3.15; = 0.79), or side consequences. However, it was shown that the medicine might help reduce BMI and weight combined with a healthy diet and regular exercise. A lifestyle change may have favorable consequences that will be assessed in the future for adjunctive therapy. PROSPERO database (CRD42022347472).
在过去几十年里，儿童肥胖已成为一个重大的全球健康问题，全球约有1.077亿儿童和青少年受其影响。目前，儿科人群中用于治疗儿童肥胖的药物疗法使用极少。本研究评估了利拉鲁肽治疗儿童和青少年肥胖的疗效。截至2022年10月20日，利用PubMed、Scopus、科学网和Embase数据库进行了系统的文献综述。使用了搜索词“利拉鲁肽”“儿童肥胖”“儿童”和“青少年”。通过该搜索方法，共找到185篇文章。纳入了三项证明利拉鲁肽治疗儿童和青少年肥胖有效性的研究。所选研究在美国进行。作为干预措施，以最大剂量3.0毫克给296名参与者使用利拉鲁肽。所有纳入试验均为3期试验。这项综合分析显示，利拉鲁肽与体重（千克；MD -2.62；95%CI -6.35至1.12； = 0.17）和体重指数（千克/米；MD -0.80；95%CI -2.33至0.73， = 0.31）之间无临床显著差异。没有证据表明利拉鲁肽会增加低血糖发作次数（RR 1.08；95%CI 0.37至3.15； = 0.79）或副作用。然而，研究表明，该药物结合健康饮食和定期锻炼可能有助于降低体重指数和体重。生活方式的改变可能会产生有利影响，未来将对其作为辅助治疗进行评估。PROSPERO数据库（CRD42022347472）
